Thurman Joshua M, Nester Carla M
Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado; and.
Stead Family Department of Pediatrics and.
Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1856-1866. doi: 10.2215/CJN.01710216. Epub 2016 Jun 23.
The complement (C) cascade is an ancient system of proteins whose primary role is to initiate and modulate immune responses. During C activation, circulating proteins are cleaved and nascent cleavage fragments participate in a broad range of downstream innate and adaptive immune functions. Although the majority of these functions are either homeostatic or protective, a large body of experimental and clinical evidence also highlights a central role for the C system in the pathogenesis of many types of glomerular disease. From classic pathway activation in lupus nephritis to alternative pathway dysregulation in C3 glomerulopathy, our understanding of the spectrum of C involvement in kidney disease has expanded greatly in recent years. However, the characteristics that make the glomerulus so uniquely susceptible to C-mediated injury are not fully understood, and this remains an area of ongoing investigation. Several C inhibitors have been approved for clinical use, and additional C inhibitory drugs are in development. The use of these drugs in patients with kidney disease will expand our understanding of the benefits and limitations of C inhibition.
补体(C)级联反应是一个古老的蛋白质系统,其主要作用是启动和调节免疫反应。在补体激活过程中,循环蛋白被裂解,新生的裂解片段参与广泛的下游固有免疫和适应性免疫功能。尽管这些功能大多是稳态性的或具有保护作用,但大量的实验和临床证据也凸显了补体系统在多种肾小球疾病发病机制中的核心作用。从狼疮性肾炎中的经典途径激活到C3肾小球病中的替代途径失调,近年来我们对补体参与肾脏疾病范围的理解有了很大扩展。然而,使肾小球如此独特地易受补体介导损伤的特征尚未完全明确,这仍是一个正在进行研究的领域。几种补体抑制剂已获批用于临床,还有其他补体抑制药物正在研发中。这些药物在肾病患者中的应用将拓展我们对补体抑制的益处和局限性的认识。